Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | HPN | P05981 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30130048 | 0.90 | SMN1; SMN2 (0.56) | NQO2SMN1; SMN2KDM4ACACNA1HCACNA1B | |
| SCHEMBL30469092 | 0.84 | KDM4A (0.54) | SMN1; SMN2KDM4ACACNA1HCACNA1BCACNA1C | |
| SCHEMBL25677972 | 0.84 | KDM4A (0.54) | SMN1; SMN2KDM4ACACNA1HCACNA1BCACNA1C | |
| SCHEMBL30920299 | 0.80 | SMN1; SMN2 (0.51) | NQO2SMN1; SMN2KDM4ACACNA1HCACNA1B | |
| SCHEMBL30920282 | 0.80 | CACNA1H (0.46) | NQO2SMN1; SMN2KDM4ACACNA1HCACNA1B | |
| SCHEMBL19964841 | 0.80 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4ACACNA1HCACNA1BCACNA1C | |
| SCHEMBL27247736 | 0.79 | CA2 (0.43) | SMN1; SMN2MTNR1AMTNR1BOPRK1CA2 | |
| SCHEMBL27247248 | 0.79 | MTNR1A (0.51) | SMN1; SMN2MTNR1AMTNR1BOPRK1CA2 | |
| SCHEMBL19964551 | 0.79 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4ACACNA1HCACNA1BCACNA1C | |
| SCHEMBL19964287 | 0.79 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4ACACNA1HCACNA1BCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601635-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | SLC6A19, SLC2A9, SLC6A3 | NQO2 1120/4885SMN1; SMN2 375/4885KDM4A 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.